文献速递血管炎

静脉英夫利西单抗与皮下阿达木单抗治疗大动脉炎疗效比较:一项多中心回顾性研究

Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: a multicentre retrospective study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

这项多中心回顾性研究纳入135例大动脉炎患者,比较静脉英夫利西单抗(IFX,n=101)与皮下阿达木单抗(ADA,n=34)的疗效。6个月时71%实现完全缓解(ADA组68% vs IFX组73%,P=0.8),12个月复发风险分别为16.8%与10.9%,血运重建发生率无显著差异;作者认为两种TNF-α抑制剂均有效。

要点

  • 6个月完全缓解率ADA组68% vs IFX组73%(P=0.8),无显著差异。
  • 12个月复发风险ADA组16.8% vs IFX组10.9%,治疗失败累积发生率无显著差异。
  • 血运重建总体发生率两组无显著差异,作者认为IFX与ADA均对大动脉炎有效。

核心结论

  • 作者认为IFX与ADA在大动脉炎中均有效,复发风险与血运重建风险无显著差异。

研究设计与样本

  • 多中心回顾性研究,在法国、意大利、西班牙、亚美尼亚、以色列、日本、突尼斯和俄罗斯的转诊中心分析2017年1月至2019年9月接受生物靶向治疗的大动脉炎患者。
  • 共纳入135例接受ADA(n=34)或IFX(n=101)至少3个月的大动脉炎患者。

主要发现

  • 6个月时71%实现完全缓解(NIH<2且泼尼松<7.5 mg/天),ADA组68% vs IFX组73%(P=0.8)。
  • 单因素分析中与6个月TNF-α抑制剂完全缓解相关的因素为年龄<30岁、吸烟、生物制剂启动时血管征象、NIH≥2、CRP>20 mg/l、泼尼松起始剂量>20 mg/天,而非使用IFX或ADA。
  • IFX与ADA患者治疗失败的累积发生率无显著差异。
  • IFX与ADA患者中位随访分别为23(17,42)个月和48(25,99)个月,12个月复发风险分别为10.9%[0,21.9]和16.8%[8.64,24.27]。
  • 血运重建总体发生率无显著差异。

关键数值与推荐

  • 完全缓解定义为NIH<2且泼尼松<7.5 mg/天。
  • IFX与ADA患者6个月完全缓解率分别为73%与68%(P=0.8)。
  • IFX与ADA患者12个月复发风险分别为10.9%[0,21.9]与16.8%[8.64,24.27]。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In this large multicentre study, we aimed to compare the effectiveness of intravenous infliximab (IFX) vs subcutaneous adalimumab (ADA) in patients with Takayasu arteritis (TAK). METHODS: We conducted a retrospective multicentre study across referral centres in France, Italy, Spain, Armenia, Israel, Japan, Tunisia, and Russia, analysing biologic targeted therapies in TAK from January 2017 to September 2019. RESULTS: A total of 135 TAK patients who received ADA (n = 34) or IFX (n = 101) for at least 3 months were included. Baseline demographics, TAK characteristics and concurrent treatments were comparable, except for a higher rate of Numano type V in the ADA group. At 6 months, 71% achieved complete response (NIH <2 with <7.5 mg/day prednisone), including 68% on ADA and 73% on IFX (P = 0.8). The factors associated with complete response to TNF-α inhibitors at 6 months in univariate analysis were age <30 years, tobacco use, vascular signs at the biologic initiation, NIH ≥2, CRP >20 mg/l, a starting dose >20 mg/day of prednisone, but not the use of either IFX or ADA. The cumulative incidence of treatment failure was not significantly different between IFX and ADA patients. During the median [IQR] follow-up of 23 [17, 42] and 48 [25, 99] months in patients who received i.v. IFX and s.c. ADA, respectively, the risk of relapse at 12 months was 10.9% [0, 21.9] and 16.8% [8.64, 24.27], respectively. The overall incidence of revascularizations was not significantly different. CONCLUSION: In this study, we confirm that IFX and ADA are both effective in TAK, without significant differences in the risk of relapse and revascularizations.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Mekinian A, Meneses S, Biard L, et al. Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: a multicentre retrospective study. Rheumatology (Oxford). 2025. PMID: 40811657. doi:10.1093/rheumatology/keaf341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。